secwatch.observer — SEC 8-K summary
======================================

Issuer:     TScan Therapeutics, Inc. (TCRX)
CIK:        0001783328
Form:       8-K
Filed at:   2023-07-25T23:59:59+00:00
Accession:  0001193125-23-192484
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TScan Therapeutics CFO Brian Silver resigns; CEO MacBeath appointed interim CFO, Dworak as Principal Accounting Officer
--------------------------------------------------------------------------------

- Brian Silver resigned as CFO, effective July 21, 2023; CEO Gavin MacBeath named interim Principal Financial Officer.
- Leiden Dworak appointed Principal Accounting Officer, effective July 21, 2023; previously VP, Finance since April 2022.
- Dworak's base salary increased to $340,000; target bonus raised to 35% from 30%; granted 25,000 stock options at $2.23.
- Stock options vest over four years (25% one-year cliff, then monthly). No family relationships or related party transactions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1783328/000119312523192484/0001193125-23-192484-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1783328/000119312523192484/d845896d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-192484

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer